|
|
A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor
Philippe Le Bouteiller
,
Julie Tabiasco
,
Jérôme Giustiniani
,
Armand Bensussan
Journal articles
inserm-02168009v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.
Jérôme Giustiniani
,
Armand Bensussan
,
Anne Marie-Cardine
Journal of Immunology, 2009, 182 (1), pp.63-71
Journal articles
inserm-00352331v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models
Thierry Menguy
,
Anne Briaux
,
Elisabeth Jeunesse
,
Jérôme Giustiniani
,
Alexandre Calcei
,
et al.
Journal articles
hal-03379522v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231
Christian Garbar
,
Corinne Mascaux
,
Jérôme Giustiniani
,
Yacine Merrouche
,
Armand Bensussan
Journal articles
hal-03424972v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway
Emilie Laprevotte
,
Stéphanie Cochaud
,
Stanislas Du Manoir
,
Marion Lapierre
,
Cécile Dejou
,
et al.
Journal articles
hal-02382938v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|